ReviewInternational journal of molecular sciences2017
Dry Eye Management: Targeting the Ocular Surface Microenvironment.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it, 266 citations in OpenAlex.
- Bridging the gap in managing dry eye disease: a consensus report by the Taiwan society of cataract and refractive surgeons.BMC ophthalmology · 2024Guideline
- A Systematic Review of Tear Vascular Endothelial Growth Factor and External Eye Diseases.International journal of molecular sciences · 2024Pooled it
- Corneal lymphangiogenesis as a potential target in dry eye disease - a systematic review.Survey of ophthalmologyPooled it
- Potential role of the ocular surface microbiome in dry eye: microbial interactions and symptom alleviation.mSystems · 2026Trial
- Real-World Transition to a Preservative-Free Fixed Combination of Dorzolamide/Timolol: Impact on the Ocular Surface Microenvironment, Safety, Tolerability, and Efficacy.Medicina (Kaunas, Lithuania) · 2026Trial
- Comparative efficacy of Shatavari Ghrita eye drops with Shatavari Ksheerapaka versus Triphala Ghrita eye drops with Shatavari Ksheerapaka in postmenopausal ocular surface disease: a randomized, single-blind trial.Frontiers in medicine · 2026Trial
- Comparison of therapeutic effects of 0.05% Cyclosporine A versus 0.1% Fluorometholone in Chinese patients with mild dry eye unresponsive to artificial tears: a randomized control study.BMC ophthalmology · 2024Trial
- Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.BMC ophthalmology · 2024Trial
- Effects of Carboxymethylcellulose Artificial Tears on Ocular Surface Microbiome Diversity and Composition, A Randomized Controlled Trial.Translational vision science & technology · 2023Trial
- The Impact of a Smartphone Reminder Application on Artificial Tear Adherence in Dry Eye Disease.Journal of clinical medicine · 2026Article
- mRNA and microRNA Expression Profile of Corneal and Conjunctival Impression Cytology Samples.Biology · 2026Article
- Tear Fluid Lymphotoxin-Alpha as a Diagnostic Biomarker for the Stratification of Dry Eye Disease.Translational vision science & technology · 2026Article
- Enhanced ocular delivery of tacrolimus via cationic nanoliposomes: Mitigating inflammation and rebalancing Th17/Treg responses in dry eye disease.Materials today. Bio · 2026Article
- Micelle-Based Ocular Inserts for Sustained Delivery and Improved Corneal Permeation of Rebamipide in Dry Eye Disease.Pharmaceutics · 2026Article
- Integrated Evaluation of Corneal Damage, Goblet Cell Remodeling and Inflammatory Response in a Murine Model of Environmental Dry Eye Disease (DED).Biomedicines · 2026Article
- Simultaneous quantification of lifitegrast and Rebamipide in hydrogel-based contact lenses using spectroscopic method.International ophthalmology · 2026Article
- Correlation analysis between ocular surface parameters and corneal higher-order aberrations in dry eye disease: a cross-sectional study.BMC ophthalmology · 2026Article
- Emerging mechanisms in dry eye disease: apoptosis-associated tear MicroRNAs and toxicant-related alterations of the glycocalyx and lipid rafts.Frontiers in ophthalmology · 2026Article
- Metagenomic profiling of ocular surface microbiome alterations in patients with progressive supranuclear palsy-Richardson's syndrome.Current research in microbial sciences · 2026Article
- Breast cancer-related endocrine therapy on ocular surface microbiota: mechanism and clinical significance.International journal of ophthalmology · 2026Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye can damage the ocular surface and result in mild corneal epithelial defect to blinding corneal pannus formation and squamous metaplasia. Significant progress in the treatment of dry eye has been made in the last two decades; progressing from lubricating and hydrating the ocular surface with artificial tear to stimulating tear secretion; anti-inflammation and immune regulation. With the increase in knowledge regarding the pathophysiology of dry eye, we propose in this review the concept of ocular surface microenvironment. Various components of the microenvironment contribute to the homeostasis of ocular surface. Compromise in one or more components can result in homeostasis disruption of ocular surface leading to dry eye disease. Complete evaluation of the microenvironment component changes in dry eye patients will not only lead to appropriate diagnosis, but also guide in timely and effective clinical management. Successful treatment of dry eye should be aimed to restore the homeostasis of the ocular surface microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.